Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)

Launched by CHINA-JAPAN FRIENDSHIP HOSPITAL · May 5, 2025

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Newly diagnosed diabetes, with no previous use of hypoglycemic medications or having discontinued such medications for more than 3 months.
• • Blood glucose elevation detected within one year (fasting blood glucose exceeding 7 mmol/L, postprandial blood glucose or random blood glucose exceeding 11.1 mmol/L).
• • Age between 30 and 70 years (inclusive of boundary values).
• • Hemoglobin A1c between 7% and 10% (inclusive of boundary values).
• • BMI between 24 and 32.5 kg/m² (inclusive of boundary values).
• Exclusion Criteria:
• • History of coronary heart disease or cerebral infarction.
• • Severe liver or kidney disease: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 times the upper limit of normal (ULN); glomerular filtration rate less than 30 ml/min/1.73 m².
• • History of malignant tumors.
• • Use of systemic glucocorticoids (excluding local applications or inhalants) for one week or more within the three months prior to screening.
• • Positive urine pregnancy test in women of childbearing age.
• • History of pancreatitis, or amylase and/or lipase \> 3 times the ULN.
• • Personal history or family history of medullary thyroid carcinoma (MTC) in first-degree relatives, or genetic predisposition to MTC (such as multiple endocrine neoplasia syndrome).